about
Guillain-Barré syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case series.Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.Deconstruction of Interhospital Transfer Workflow in Large Vessel Occlusion: Real-World Data in the Thrombectomy Era.Beyond Neglect: Preliminary Evidence of Retrospective Time Estimation Abnormalities in Non-Neglect Stroke and Transient Ischemic Attack Patients.Diagnosis and management of gastric leaks after laparoscopic sleeve gastrectomy for morbid obesity.Systematic Review of Guidelines for the Management of Asymptomatic and Symptomatic Carotid Stenosis.Migraine: Does aura require investigation?Pringle manoeuvre versus selective hepatic vascular exclusion: outcome of a case series in a tertiary referral centre.Residency training: Advocacy training in neurology: lessons from the Palatucci Advocacy Leadership Forum.STroke imAging pRevention and treatment (START): A longitudinal stroke cohort study: Clinical trials protocol.A multicenter, randomized, controlled study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits with Intra-Arterial therapy (EXTEND-IA).Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells.The perception of positive and negative facial expressions by unilateral stroke patients.A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND).The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial.Balance and Gait Impairment in Transient Ischemic Attack and Minor Stroke.Corrosive acid injury of the stomach.
P50
Q30423780-E1E8A044-1984-4609-BB7F-025C647E36CBQ33966647-20438040-6AED-41B0-8BEB-6F049CC2697BQ36373616-2ED2A262-3618-4949-8FB3-199B8E37C230Q36651173-AED5DA2C-64C7-438E-8F53-7E9DC6E91430Q37638370-91C8B7D9-9B76-4519-A963-8ADAE2E626B0Q38602948-B4AD323F-CEC7-40D4-A9A2-A89B9B50FA9EQ38839342-27595638-A050-47BF-85EB-9F716413A304Q41629079-D7DF8C2B-F026-4C53-83E1-CA01F3B85EC9Q44909615-E8E22EEA-7D76-4065-9A6F-987891D6881BQ45923718-5026C20F-7CD5-4D56-A147-4EB9FB90D47CQ46612385-6770C358-0E02-4C6E-97BC-FD47F3162345Q47835160-329F43DA-D0BD-4C69-8C48-21167A17A159Q47913506-A33D8D36-60F8-468E-AC3B-B560A1099BF4Q48268410-C9DD7A78-13B7-4A99-A59B-A639840D47D3Q50694058-484BC371-8F98-4DEA-B049-80D40486E2BAQ53401029-A2ED1BC2-DD10-4EAB-80D3-05CD79219DADQ54492228-DCF93CF6-1DBD-45F0-9A4D-6F7669B2F761
P50
description
researcher (ORCID 0000-0003-3341-9310)
@en
name
Tissa Wijeratne
@en
type
label
Tissa Wijeratne
@en
prefLabel
Tissa Wijeratne
@en
P31
P496
0000-0003-3341-9310